| Segment Reporting [Table Text Block] |
| Three Months Ended June 30, 2026 | |
| | | Regenerative Biotech | | | Consumer Health Products | | | Consolidated Total | |
| Revenue | |
| Product revenue | | $ | — | | | $ | 414 | | | $ | 414 | |
| Significant Expense Categories (provided to CODM) | |
| Cost of sales | | | — | | | | 391 | | | | 391 | |
| Research and development | | | 948 | | | | — | | | | 948 | |
| Sales and marketing | | | — | | | | 16 | | | | 16 | |
| General and administrative (a) | | | 750 | | | | 1 | | | | 751 | |
| Total significant segment expenses | | | 1,698 | | | | 408 | | | | 2,106 | |
| Other Segment Items | |
| Other segment items (b) | | | (3 | ) | | | — | | | | (3 | ) |
| Segment net loss | | $ | (1,701 | ) | | $ | 6 | | | $ | (1,695 | ) |
| | | | | | | | | | | | | |
| Three Months Ended June 30, 2025 | |
| | | Regenerative Biotech | | | Consumer Health Products | | | Consolidated Total | |
| Revenue | |
| Product revenue | | $ | — | | | $ | 317 | | | $ | 317 | |
| Significant Expense Categories (provided to CODM) | |
| Cost of sales | | | — | | | | 302 | | | | 302 | |
| Research and development | | | 697 | | | | — | | | | 697 | |
| General and administrative (a) | | | 1,150 | | | | 1 | | | | 1,151 | |
| Total significant segment expenses | | | 1,847 | | | | 303 | | | | 2,150 | |
| Other Segment Items | |
| Other segment items (b) | | | 10 | | | | — | | | | 10 | |
| Segment net loss | | $ | (1,837 | ) | | $ | 14 | | | $ | (1,823 | ) |
| | | | | | | | | | | | | |
| Six Months Ended June 30, 2026 | |
| | | Regenerative Biotech | | | Consumer Health Products | | | Consolidated Total | |
| Revenue | |
| Product revenue | | $ | — | | | $ | 640 | | | $ | 640 | |
| Significant Expense Categories (provided to CODM) | |
| Cost of sales | | | — | | | | 597 | | | | 597 | |
| Research and development | | | 1,511 | | | | — | | | | 1,511 | |
| Sales and marketing | | | 2 | | | | 32 | | | | 34 | |
| General and administrative (a) | | | 1,794 | | | | 2 | | | | 1,796 | |
| Total significant segment expenses | | | 3,307 | | | | 631 | | | | 3,938 | |
| Other Segment Items | |
| Other segment items (b) | | | 2 | | | | — | | | | 2 | |
| Segment net loss | | $ | (3,305 | ) | | $ | 9 | | | $ | (3,296 | ) |
| Six Months Ended June 30, 2025 | |
| | | Regenerative Biotech | | | Consumer Health Products | | | Consolidated Total | |
| Revenue | |
| Product revenue | | $ | — | | | $ | 362 | | | $ | 362 | |
| Significant Expense Categories (provided to CODM) | |
| Cost of sales | | | — | | | | 335 | | | | 335 | |
| Research and development | | | 1,298 | | | | — | | | | 1,298 | |
| Sales and marketing | | | 9 | | | | 1 | | | | 10 | |
| General and administrative (a) | | | 2,221 | | | | 1 | | | | 2,222 | |
| Total significant segment expenses | | | 3,528 | | | | 337 | | | | 3,865 | |
| Other Segment Items | |
| Other segment items (b) | | | 21 | | | | — | | | | 21 | |
| Segment net loss | | $ | (3,507 | ) | | $ | 25 | | | $ | (3,482 | ) |
|
| Segment Reporting, Reconciliation of Asset by Segment to Consolidated [Table Text Block] |
| | | June 30, | | | December 31, | |
| | | 2026 | | | 2025 | |
| Cash and cash equivalents: | | | | | | | | |
| Regenerative Biotech | | $ | 24 | | | $ | 1,206 | |
| Consumer Health Products | | | 327 | | | | 146 | |
| Total | | $ | 351 | | | $ | 1,352 | |
| | | | | | | | | |
| Total assets: | | | | | | | | |
| Regenerative Biotech | | $ | 1,091 | | | $ | 2,277 | |
| Consumer Health Products | | | 594 | | | | 400 | |
| Total | | $ | 1,685 | | | $ | 2,677 | |
|